+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Colorectal Cancer Drugs Market Research Report by Class (Chemotherapy and Immunotherapy), Type, Distribution Channel, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 238 Pages
  • July 2022
  • Region: Global
  • 360iResearch™
  • ID: 4896776
UP TO OFF until Dec 31st 2022
The Global Colorectal Cancer Drugs Market size was estimated at USD 9,882.63 million in 2021, USD 10,347.35 million in 2022, and is projected to grow at a CAGR 4.87% to reach USD 13,152.73 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Colorectal Cancer Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Class, the market was studied across Chemotherapy and Immunotherapy. The Chemotherapy is further studied across 5-Fluorouracil (5-FU), Capecitabine (Xeloda), a pill that is changed into 5-FU once it gets to the tumor., Irinotecan (Camptosar), Oxaliplatin (Eloxatin), and Trifluridine and tipiracil (Lonsurf),. The Immunotherapy is further studied across CTLA-4 Inhibitor, KRAS Inhibitor, and PD-1 Inhibitors.
  • Based on Type, the market was studied across BRAF or MEK Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Immunomodulators, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, Tyrosine Kinase (TKI) Inhibitors, and Vascular Endothelial Growth Factor (VEGF) Inhibitors.
  • Based on Distribution Channel, the market was studied across Hospitals Pharmacies and Retail Pharmacies.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Colorectal Cancer Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Colorectal Cancer Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Colorectal Cancer Drugs Market, including 3SBio, AbbVie Inc., Amgen, Astellas Pharma Inc., AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Celgene, Cernostics, Cerus Corporation, CHAIN Biotechnology, Daiichi Sankyo, DNALite Therapeutics, Inc., Eli Lilly, Gilead Sciences, GlaxoSmithKline, Helix, Immunocore, Incyte Corp, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi, Spectrum Pharmaceuticals, Inc., and Takeda.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Colorectal Cancer Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Colorectal Cancer Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Colorectal Cancer Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Colorectal Cancer Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Colorectal Cancer Drugs Market?
6. What is the market share of the leading vendors in the Global Colorectal Cancer Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Colorectal Cancer Drugs Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increases identification and prevalence of colon cancer
5.1.1.2. Continuous drug development and investment in immunotherapies
5.1.2. Restraints
5.1.2.1. Potentially unmeasured side effects
5.1.3. Opportunities
5.1.3.1. Investment driven oncology segemnt
5.1.3.2. Introduction and increased availability of generics and biologics
5.1.4. Challenges
5.1.4.1. Affordability of patented drugs
5.2. Cumulative Impact of COVID-19
6. Colorectal Cancer Drugs Market, by Class
6.1. Introduction
6.2. Chemotherapy
6.2.1. 5-Fluorouracil (5-FU)
6.2.2. Capecitabine (Xeloda), a pill that is changed into 5-FU once it gets to the tumor.
6.2.3. Irinotecan (Camptosar)
6.2.4. Oxaliplatin (Eloxatin)
6.2.5. Trifluridine and tipiracil (Lonsurf),
6.3. Immunotherapy
6.3.1. CTLA-4 Inhibitor
6.3.2. KRAS Inhibitor
6.3.3. PD-1 Inhibitors
7. Colorectal Cancer Drugs Market, by Type
7.1. Introduction
7.2. BRAF or MEK Inhibitors
7.3. Epidermal Growth Factor Receptor (EGFR) Inhibitors
7.4. Immunomodulators
7.5. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
7.6. Tyrosine Kinase (TKI) Inhibitors
7.7. Vascular Endothelial Growth Factor (VEGF) Inhibitors
8. Colorectal Cancer Drugs Market, by Distribution Channel
8.1. Introduction
8.2. Hospitals Pharmacies
8.3. Retail Pharmacies
9. Americas Colorectal Cancer Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Colorectal Cancer Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Colorectal Cancer Drugs Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. 3SBio
13.2. AbbVie Inc.
13.3. Amgen
13.4. Astellas Pharma Inc.
13.5. AstraZeneca
13.6. Bayer
13.7. BeiGene
13.8. Bristol-Myers Squibb
13.9. Celgene
13.10. Cernostics
13.11. Cerus Corporation
13.12. CHAIN Biotechnology
13.13. Daiichi Sankyo
13.14. DNALite Therapeutics, Inc.
13.15. Eli Lilly
13.16. Gilead Sciences
13.17. GlaxoSmithKline
13.18. Helix
13.19. Immunocore
13.20. Incyte Corp
13.21. Johnson & Johnson
13.22. Merck & Co., Inc.
13.23. Novartis AG
13.24. Pfizer Inc.
13.25. Roche Holding AG
13.26. Sanofi
13.27. Spectrum Pharmaceuticals, Inc.
13.28. Takeda
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL COLORECTAL CANCER DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2027
FIGURE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET DYNAMICS
FIGURE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2021 VS 2027 (%)
FIGURE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2027
FIGURE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2019-2027 (USD MILLION)
FIGURE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY 5-FLUOROURACIL (5-FU), 2019-2027 (USD MILLION)
FIGURE 14. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY 5-FLUOROURACIL (5-FU), BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 15. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CAPECITABINE (XELODA), A PILL THAT IS CHANGED INTO 5-FU ONCE IT GETS TO THE TUMOR., 2019-2027 (USD MILLION)
FIGURE 16. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CAPECITABINE (XELODA), A PILL THAT IS CHANGED INTO 5-FU ONCE IT GETS TO THE TUMOR., BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 17. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IRINOTECAN (CAMPTOSAR), 2019-2027 (USD MILLION)
FIGURE 18. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IRINOTECAN (CAMPTOSAR), BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 19. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OXALIPLATIN (ELOXATIN), 2019-2027 (USD MILLION)
FIGURE 20. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OXALIPLATIN (ELOXATIN), BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 21. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TRIFLURIDINE AND TIPIRACIL (LONSURF),, 2019-2027 (USD MILLION)
FIGURE 22. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TRIFLURIDINE AND TIPIRACIL (LONSURF),, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 23. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2019-2027 (USD MILLION)
FIGURE 24. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 25. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITOR, 2019-2027 (USD MILLION)
FIGURE 26. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 27. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY KRAS INHIBITOR, 2019-2027 (USD MILLION)
FIGURE 28. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY KRAS INHIBITOR, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 29. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 30. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 31. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 32. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2027
FIGURE 34. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF OR MEK INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 35. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF OR MEK INHIBITORS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 36. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 37. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 38. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOMODULATORS, 2019-2027 (USD MILLION)
FIGURE 39. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 40. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1/PD1 LIGAND 1 (PD1/PDL1) INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 41. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1/PD1 LIGAND 1 (PD1/PDL1) INHIBITORS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 42. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE (TKI) INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 43. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE (TKI) INHIBITORS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 44. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS, 2019-2027 (USD MILLION)
FIGURE 45. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 46. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 47. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD MILLION)
FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2027
FIGURE 49. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, 2019-2027 (USD MILLION)
FIGURE 50. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 51. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2019-2027 (USD MILLION)
FIGURE 52. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 53. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 54. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 55. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 56. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2027
FIGURE 57. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 58. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 59. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 60. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 61. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 62. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 63. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 64. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2027
FIGURE 65. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 66. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 67. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 68. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2027
FIGURE 69. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 70. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 71. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 72. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 73. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 74. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 75. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 76. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 77. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 78. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 79. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 80. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 81. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 82. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 83. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2027
FIGURE 84. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 85. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 86. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 87. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 88. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 89. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 90. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 91. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 92. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 93. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 94. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 95. GLOBAL COLORECTAL CANCER DRUGS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 96. GLOBAL COLORECTAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 97. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL COLORECTAL CANCER DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL COLORECTAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 6. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2019-2027 (USD MILLION)
TABLE 7. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 10. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY 5-FLUOROURACIL (5-FU), BY REGION, 2019-2027 (USD MILLION)
TABLE 12. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY 5-FLUOROURACIL (5-FU), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY 5-FLUOROURACIL (5-FU), BY STATE, 2019-2027 (USD MILLION)
TABLE 14. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY 5-FLUOROURACIL (5-FU), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 15. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY 5-FLUOROURACIL (5-FU), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CAPECITABINE (XELODA), A PILL THAT IS CHANGED INTO 5-FU ONCE IT GETS TO THE TUMOR., BY REGION, 2019-2027 (USD MILLION)
TABLE 17. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY CAPECITABINE (XELODA), A PILL THAT IS CHANGED INTO 5-FU ONCE IT GETS TO THE TUMOR., BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 18. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CAPECITABINE (XELODA), A PILL THAT IS CHANGED INTO 5-FU ONCE IT GETS TO THE TUMOR., BY STATE, 2019-2027 (USD MILLION)
TABLE 19. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY CAPECITABINE (XELODA), A PILL THAT IS CHANGED INTO 5-FU ONCE IT GETS TO THE TUMOR., BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 20. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CAPECITABINE (XELODA), A PILL THAT IS CHANGED INTO 5-FU ONCE IT GETS TO THE TUMOR., BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 21. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IRINOTECAN (CAMPTOSAR), BY REGION, 2019-2027 (USD MILLION)
TABLE 22. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY IRINOTECAN (CAMPTOSAR), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 23. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY IRINOTECAN (CAMPTOSAR), BY STATE, 2019-2027 (USD MILLION)
TABLE 24. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY IRINOTECAN (CAMPTOSAR), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 25. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IRINOTECAN (CAMPTOSAR), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 26. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY OXALIPLATIN (ELOXATIN), BY REGION, 2019-2027 (USD MILLION)
TABLE 27. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY OXALIPLATIN (ELOXATIN), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 28. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY OXALIPLATIN (ELOXATIN), BY STATE, 2019-2027 (USD MILLION)
TABLE 29. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY OXALIPLATIN (ELOXATIN), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 30. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY OXALIPLATIN (ELOXATIN), BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 31. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TRIFLURIDINE AND TIPIRACIL (LONSURF),, BY REGION, 2019-2027 (USD MILLION)
TABLE 32. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TRIFLURIDINE AND TIPIRACIL (LONSURF),, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 33. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TRIFLURIDINE AND TIPIRACIL (LONSURF),, BY STATE, 2019-2027 (USD MILLION)
TABLE 34. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY TRIFLURIDINE AND TIPIRACIL (LONSURF),, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 35. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TRIFLURIDINE AND TIPIRACIL (LONSURF),, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 36. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2019-2027 (USD MILLION)
TABLE 37. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 38. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY STATE, 2019-2027 (USD MILLION)
TABLE 39. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 40. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 41. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2019-2027 (USD MILLION)
TABLE 42. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITOR, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 43. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITOR, BY STATE, 2019-2027 (USD MILLION)
TABLE 44. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITOR, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 45. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CTLA-4 INHIBITOR, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 46. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY KRAS INHIBITOR, BY REGION, 2019-2027 (USD MILLION)
TABLE 47. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY KRAS INHIBITOR, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 48. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY KRAS INHIBITOR, BY STATE, 2019-2027 (USD MILLION)
TABLE 49. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY KRAS INHIBITOR, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY KRAS INHIBITOR, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 51. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2019-2027 (USD MILLION)
TABLE 52. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 53. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 54. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 56. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 57. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF OR MEK INHIBITORS, BY REGION, 2019-2027 (USD MILLION)
TABLE 58. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF OR MEK INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 59. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF OR MEK INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 60. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF OR MEK INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY BRAF OR MEK INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 62. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS, BY REGION, 2019-2027 (USD MILLION)
TABLE 63. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 64. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 65. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 67. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2019-2027 (USD MILLION)
TABLE 68. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 69. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 70. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 72. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1/PD1 LIGAND 1 (PD1/PDL1) INHIBITORS, BY REGION, 2019-2027 (USD MILLION)
TABLE 73. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1/PD1 LIGAND 1 (PD1/PDL1) INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 74. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1/PD1 LIGAND 1 (PD1/PDL1) INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 75. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1/PD1 LIGAND 1 (PD1/PDL1) INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY PROGRAMMED CELL DEATH PROTEIN 1/PD1 LIGAND 1 (PD1/PDL1) INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 77. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE (TKI) INHIBITORS, BY REGION, 2019-2027 (USD MILLION)
TABLE 78. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE (TKI) INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 79. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE (TKI) INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 80. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE (TKI) INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE (TKI) INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 82. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS, BY REGION, 2019-2027 (USD MILLION)
TABLE 83. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 84. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS, BY STATE, 2019-2027 (USD MILLION)
TABLE 85. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 87. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 88. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2019-2027 (USD MILLION)
TABLE 89. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 90. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 91. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 93. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2019-2027 (USD MILLION)
TABLE 94. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 95. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2019-2027 (USD MILLION)
TABLE 96. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 98. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 99. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 100. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 101. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 102. AMERICAS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 103. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 104. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 105. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 106. ARGENTINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 107. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 108. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 109. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 110. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 111. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 112. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 113. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 114. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 115. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 116. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 117. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 118. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 119. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 120. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 121. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 122. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 123. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 124. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 125. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 126. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 127. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 128. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 129. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 130. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 131. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 132. AUSTRALIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 133. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 134. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 135. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 136. CHINA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 137. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 138. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 139. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 140. INDIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 141. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 142. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 143. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 144. INDONESIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 145. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 146. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 147. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 148. JAPAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 149. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 150. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 151. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 152. MALAYSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 153. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 154. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 155. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 156. PHILIPPINES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 157. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 158. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 159. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 160. SINGAPORE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 161. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 162. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 163. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 164. SOUTH KOREA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 165. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 166. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 167. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 168. TAIWAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 169. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 170. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 171. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 172. THAILAND COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 178. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 179. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 180. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 181. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 182. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 183. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 184. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 185. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 186. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 187. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 188. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 189. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 190. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 191. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 192. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 193. NETHERLANDS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 194. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 195. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 196. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 197. QATAR COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 198. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 199. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 200. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 201. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 202. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 203. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 204. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 205. SAUDI ARABIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 206. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 207. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 208. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 209. SOUTH AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 210. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 211. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 212. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 213. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 218. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 219. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY CLASS, 2019-2027 (USD MILLION)
TABLE 220. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY TYPE, 2019-2027 (USD MILLION)
TABLE 221. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 222. GLOBAL COLORECTAL CANCER DRUGS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 223. GLOBAL COLORECTAL CANCER DRUGS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 224. GLOBAL COLORECTAL CANCER DRUGS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 225. GLOBAL COLORECTAL CANCER DRUGS MARKET RANKING
TABLE 226. GLOBAL COLORECTAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 227. GLOBAL COLORECTAL CANCER DRUGS MARKET MERGER & ACQUISITION
TABLE 228. GLOBAL COLORECTAL CANCER DRUGS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 229. GLOBAL COLORECTAL CANCER DRUGS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 230. GLOBAL COLORECTAL CANCER DRUGS MARKET INVESTMENT & FUNDING
TABLE 231. GLOBAL COLORECTAL CANCER DRUGS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 232. GLOBAL COLORECTAL CANCER DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

  • 3SBio
  • AbbVie Inc.
  • Amgen
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bayer
  • BeiGene
  • Bristol-Myers Squibb
  • Celgene
  • Cernostics
  • Cerus Corporation
  • CHAIN Biotechnology
  • Daiichi Sankyo
  • DNALite Therapeutics, Inc.
  • Eli Lilly
  • Gilead Sciences
  • GlaxoSmithKline
  • Helix
  • Immunocore
  • Incyte Corp
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi
  • Spectrum Pharmaceuticals, Inc.
  • Takeda

Methodology

Loading
LOADING...